KRAS and glioblastoma: On the basis of these data, we conclude that c-Myc serves as an oncogenic driver and may be a promising target for GBM treatment; this is consistent with the results of a previous report [37]; however, Cdc20 is a passenger in GBM development and progression when combined with kRas/Akt3 oncogenic signals.